---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-029210"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2026-05-01T23:59:59+00:00"
generated_at: "2026-05-15T00:20:02.672090+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Arvinas gets FDA approval for VEPPANU (vepdegestrant) in ESR1m breast cancer; first PROTAC approved

## Summary
- FDA approved VEPPANU for ER+/HER2-, ESR1-mutated advanced/metastatic breast cancer after at least one prior endocrine therapy.
- VEPPANU is the first FDA-approved PROTAC degrader; approval came before June 5, 2026 PDUFA date.
- Arvinas to receive $50M development milestone payment from collaborator Pfizer upon approval.
- Arvinas and Pfizer on track to select third-party for VEPPANU commercialization.
- Phase 3 VERITAC-2: vepdegestrant reduced risk of progression or death by 43% vs fulvestrant (HR 0.57, p=0.0001).

## SEC filing metadata
- accession: 0001628280-26-029210
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2026-05-01T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000162828026029210/0001628280-26-029210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000162828026029210/arvn-20260501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-029210
- JSON: https://secwatch.observer/filing/0001628280-26-029210.json
- Plain text: https://secwatch.observer/filing/0001628280-26-029210.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.